Covista vs Laureate Education
CVSA and LAUR side by side, both in services-educational services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVSA and LAUR compare
Laureate Education is the larger company, worth 1.2 times as much as Covista ($4.8B against $3.9B).
On earnings, Laureate Education is cheaper: it trades at 12.8× trailing earnings, against 16.1× for Covista.
Laureate Education grew revenue faster over the last twelve months (20.9% versus 9.3% for Covista).
Laureate Education keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with 12.8% at Covista.
Covista scores higher on the StockData Score (18 against 17 for Laureate Education), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVSA | LAUR |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $4.8B |
| Share price | $118.17 | $35.03 |
| Change, 1 year | 22.0% | 12.5% |
| Change, 5 years | 286% | 218% |
| Beta (5Y) | 0.84 | 0.57 |
| Employees | 510 | 34K |
| StockData Score | ||
| Total score | 18 (better) | 17 |
| Valuation score | 3 (better) | 2 |
| Growth score | 5 | 5 |
| Performance score | 5 | 5 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.1× | 12.8× (better) |
| P/S | 2.0× (better) | 2.5× |
| P/B | 2.8× (better) | 4.1× |
| EV/EBITDA | 10.6× | 9.6× (better) |
| P/FCF | 11.1× (better) | 16.5× |
| PEG | 0.32 | 0.19 (better) |
| FCF yield | 9.0% (better) | 6.0% |
| Fair value | $119.25 | $34.46 |
| Margin of safety | 0.91% (better) | −1.7% |
| Growth | ||
| Revenue growth (TTM) | 9.3% | 20.9% (better) |
| Revenue growth, 5Y average | 16.8% (better) | 10.7% |
| Net income growth (TTM) | 1.8% | 90.6% (better) |
| EPS growth (TTM) | 9.6% | 99.3% (better) |
| EPS growth, 5Y average | 38.9% | – |
| Profitability | ||
| Gross margin | 57.4% (better) | 28.6% |
| Operating margin | 19.8% | 25.8% (better) |
| Net margin | 12.8% | 20.3% (better) |
| FCF margin | 17.7% (better) | 15.0% |
| Return on equity | 17.9% | 34.1% (better) |
| Return on invested capital | 17.8% | 36.1% (better) |
| Financial health | ||
| Debt / equity | 0.35 | 0.17 (better) |
| Net debt / EBITDA | 0.70 | 0.03 (better) |
| Interest coverage | 8.9× | 33.7× (better) |
| Current ratio | 0.81 (better) | 0.71 |
| Altman Z-score | 4.12 (better) | 3.77 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 8.0% | 8.5% (better) |
| Shareholder yield | 8.0% | 8.5% (better) |
| Ownership | ||
| Held by institutions | 103% | 98.5% |
| Held by insiders | 3.0% | 27.1% |
| Insider net buying, 12 months | −$6.6M (better) | −$21.9M |
| Short interest, % of float | 8.7% | 3.2% |
Go deeper
- CVSA stock overview
- CVSA income statement
- CVSA valuation and score
- LAUR stock overview
- LAUR income statement
- LAUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.